Foresite Capital Fund IV, L.P. 13D/13G Filings for Keros Therapeutics, Inc. (KROS)

Foresite Capital Fund IV, L.P. 13D and 13G filings for Keros Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-02-11
3:13 pm
Sale		 2021-12-31 13G Keros Therapeutics, Inc.
KROS		 Foresite Capital Fund IV, L.P. 0
0.000%		 -1,412,705decrease
(Position Closed)		 Filing
2021-02-16
10:56 am
Sale		 2020-12-31 13G Keros Therapeutics, Inc.
KROS		 Foresite Capital Fund IV, L.P. 1,412,705
6.100%		 -15,366decrease
(-1.08%)		 Filing